Original article| Volume 102, ISSUE 5, P828-837, November 1983

Download started.


Heparinase: in vivo activity and immunogenicity in rabbits

      This paper is only available as a PDF. To read, Please Download here.


      Anticoagulation with heparin is required during extracorporeal circulation for hemodialysis and cardiopulmonary bypass as well as during vascular surgery. Reversal of anticoagulation with protamine may be associated with hypotension and rebound anticoagulation and requires stoichiometric doses. Heparinase from Flavobacterium heparinum catalytically degrades heparin and reverses its anticoagulant effect. Heparin was administered to New Zealand White rabbits and plasma levels were assayed with the APTT anticoagulant assay and the azure A chemical assay. Heparinase actively degraded heparin both in vitro in rabbit plasma and in vivo in rabbit blood as determined by both the anticoagulant and chemical assays when compared to control heparin disappearance curves. Antibodies to heparinase were demonstrated by the ELISA technique in rabbits receiving i.v. heparinase. These antibodies, however, did not effect the activity of the enzyme in vitro or in vivo. No toxic effects of heparinase were noted in observations of the animals or in blood and histologic studies. Heparinase, either free or immobilized, may be a useful heparin-reversing agent without the drawbacks of protamine.


      (i.m.) (intramuscular(ly)), (i.v.) (intravenous(ly)), (APTT) (activated partial thromboplastin time), (ELISA) (enzyme-linked immunosorbent assay), (PBS) (phosphate-buffered saline), (SDS) (sodium dodecyl sulfate), (LDH) (lactic acid dehydrogenase), (SGOT) (serum glutamic oxaloacetic transaminase), (SGPT) (serum glutamic pyruvic transaminase)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jastrzebski J
        • Sykes MK
        • Woods DG
        Cardiorespiratory effects of protamine after cardiopulmonary bypass in man.
        Thorax. 1974; 29: 534
        • Jaques LB
        Protamine—antagonist to heparin.
        Can Med Assoc J. 1973; 108: 1291
        • Hampers CL
        • Blaufox MD
        • Merrill JP
        Anticoagulation rebound after hemodialysis.
        N Engl J Med. 1966; 275: 776
        • Langer R
        • Linhardt RJ
        • Galliher PM
        • Flanagan MM
        • Cooney CL
        • Klein MD
        A system for heparin removal.
        in: Biomaterials: Interfacial Phenomena and Applications. Advances in Chemistry Series. vol. 199. American Chemical Society, Washington D.C1982: 493
        • Langer R
        • Linhardt RJ
        • Hoffman S
        • Larson AK
        • Cooney CL
        • Tapper D
        • Klein M
        An enzymatic system for removing heparin in extracorporeal therapy.
        Science. 1982; 217: 261
        • Galliher PM
        • Cooney CL
        • Langer R
        • Linhardt RJ
        Heparinase production by Flavobacterium heparinum.
        Appl Environ Microbiol. 1981; 41: 360
        • Galliher PM
        • Lindhardt RJ
        • Conway LJ
        • Langer R
        • Cooney CL
        Regulation of heparinase synthesis in Flavobacterium heparinum.
        Eur J Appl Microbiol Biotechnol. 1982; 15: 252
        • Bjornsson TD
        • Wolfram KM
        Determinants of the anticoagulant effect of heparin in vitro.
        Ann NY Acad Sci. 1981; 370: 656
        • Klein MD
        • Drongowski RA
        • Linhardt RJ
        • Langer RS
        A colorimetric assay for chemical heparin in plasma.
        Anal Biochem. 1982; 124: 59
        • Voller A
        • Bidwell D
        • Bartlett A
        Microplate enzyme immunoassays for the immunodiagnosis of virus infections.
        in: Manual of Clinical Immunology. American Society for Microbiology, Washington D.C1976: 506
        • Payza AN
        • Korn ED
        Bacterial degradation of heparin.
        Nature. 1956; 177: 88
        • Hovingh P
        • Linker A
        The enzymatic degradation of heparin and heparitin sulfate. III. Purification of a heparitinase and a heparinase from Flavobacteria.
        J Biol Chem. 1970; 245: 6170
        • Silva ME
        • Dietrich CP
        Structure of heparin: characterization of the products formed from heparin by the action of a heparinase and a heparitinase from Flavobacterium heparinum.
        J Biol Chem. 1975; 250: 6841
        • Linhardt RJ
        • Fitzgerald GL
        • Cooney CL
        • Langer R
        Mode of action of heparin lyase on heparin.
        Biochim Biophys Acta. 1982; 702: 197
        • Linhardt RJ
        • Grant A
        • Cooney CL
        • Langer R
        Differential anticoagulant activity of heparin fragments prepared using microbial heparinase.
        J Biol Chem. 1982; 257: 7310
        • Jaques LB
        Heparin: an old drug with a new paradigm.
        Science. 1979; 206: 528
        • McAvoy TJ
        Pharmacokinetic modeling of heparin and its clinical implications.
        J Pharmacokinet Biopharmacol. 1979; 7: 331